Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Julie Roques

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5064568532. Sources: OpenAlex.

Their work

Papers
23
Trials
0
Grants
0
Labs led
0
Collaborators
72
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 3 papers · 2018: 1 paper · 2019: 2 papers · 2020: 3 papers · 2021: 5 papers · 2022: 3 papers · 2023: 1 paper · 2024: none · 2025: none · 2026: 3 papers

Papers 23

  1. Single-cell transcriptomic profiling of patient-derived pancreatic ductal adenocarcinoma primary cell cultures. Co-author DOI 10.1038/s41597-026-07380-3↗
  2. A comprehensive proteomic dataset of secretomes from primary pancreatic cancer cell cultures. Co-author DOI 10.1038/s41597-026-07902-z↗
  3. Transcriptomic FOLFIRINOX sensitivity signatures stratify overall survival and reveal directional reclassification after neoadjuvant FOLFIRINOX in borderline r… Co-author DOI 10.64898/2026.09.07.749857↗
  4. Pancreatic ductal adenocarcinoma ubiquitination profiling reveals specific prognostic and theranostic markers. Co-author DOI 10.1016/j.ebiom.2023.104634↗
  5. Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity. Co-author DOI 10.1002/cac2.12365↗
  6. Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic c… Co-author DOI 10.1016/j.tranon.2021.101315↗
  7. Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic prediction. Co-author DOI 10.1038/s41698-022-00299-z↗
  8. A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.annonc.2020.10.601↗
  9. Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance. Co-author DOI 10.1016/j.ebiom.2021.103332↗
  10. A glycosyltransferase gene signature to detect pancreatic ductal adenocarcinoma patients with poor prognosis. Co-author DOI 10.1016/j.ebiom.2021.103541↗
  11. TNF-α induces endothelial-mesenchymal transition promoting stromal development of pancreatic adenocarcinoma. Co-author DOI 10.1038/s41419-021-03920-4↗
  12. Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models. Co-author DOI 10.3390/cancers13102473↗
  13. Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2020.102858↗
  14. Basal-like and classical cells coexist in pancreatic cancer revealed by single-cell analysis on biopsy-derived pancreatic cancer organoids from the classical s… Co-author DOI 10.1096/fj.202000363rr↗
  15. Evidencing a Pancreatic Ductal Adenocarcinoma Subpopulation Sensitive to the Proteasome Inhibitor Carfilzomib. Co-author DOI 10.1158/1078-0432.ccr-20-1232↗
  16. PML hyposumoylation is responsible for the resistance of pancreatic cancer. Co-author DOI 10.1096/fj.201901091r↗
  17. Pancreatic Cancer Organoids for Determining Sensitivity to Bromodomain and Extra-Terminal Inhibitors (BETi). Co-author DOI 10.3389/fonc.2019.00475↗
  18. LIF Drives Neural Remodeling in Pancreatic Cancer and Offers a New Candidate Biomarker. Co-author DOI 10.1158/0008-5472.can-15-2790↗
  19. PAP/REG3A favors perineural invasion in pancreatic adenocarcinoma and serves as a prognostic marker. Co-author DOI 10.1007/s00018-017-2579-9↗
  20. Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts. Co-author DOI 10.1016/j.celrep.2017.11.003↗
  21. Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions. Co-author DOI 10.1038/ncomms16031↗
  22. Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness. Co-author DOI 10.1172/jci87734↗
  23. Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. Co-author DOI 10.1073/pnas.1421601112↗

Closest collaborators

The 25 strongest of 72 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Juan Iovanna · 22 shared papers, 2015–2026 · strength 2.51
  2. Nelson Dusetti · 18 shared papers, 2016–2026 · strength 2.44
  3. Odile Gayet · 15 shared papers, 2015–2026 · strength 1.74
  4. Nicolas Alejandro Fraunhoffer · 9 shared papers, 2020–2026 · strength 1.65
  5. Brice Chanez · 5 shared papers, 2022–2026 · strength 1.12
  6. Philippe Soubeyran · 6 shared papers, 2019–2026 · strength 1.07
  7. Rémy Nicolle · 8 shared papers, 2017–2022 · strength 0.82
  8. Abdessamad El Kaoutari · 5 shared papers, 2020–2023 · strength 0.63
  9. Jerome F. Cros · 6 shared papers, 2017–2022 · strength 0.56
  10. Analía Meilerman Abuelafia · 3 shared papers, 2020–2022 · strength 0.41
  11. Jean‐Baptiste Bachet · 5 shared papers, 2016–2022 · strength 0.37
  12. Marc F. Giovannini · 4 shared papers, 2017–2022 · strength 0.33
  13. Raul A. Urrutia · 3 shared papers, 2017–2022 · strength 0.32
  14. Gwen Alyce Lomberk · 3 shared papers, 2017–2022 · strength 0.32
  15. Jonathan Garnier · 2 shared papers, 2017–2026 · strength 0.31
  16. Vladimir Chocoloff · 1 shared paper, 2026 · strength 0.30
  17. Clémentine Gaucher · 1 shared paper, 2026 · strength 0.27
  18. Jean‐Luc Van Laethem · 3 shared papers, 2017–2022 · strength 0.26
  19. Eduardo Chuluyán · 2 shared papers, 2020–2022 · strength 0.26
  20. Richard Tomasini · 5 shared papers, 2015–2018 · strength 0.26
  21. Sophie Vasseur · 5 shared papers, 2015–2018 · strength 0.24
  22. Yolande Berthois · 2 shared papers, 2019–2023 · strength 0.24
  23. Owen Hoare · 2 shared papers, 2021 · strength 0.22
  24. Pauline Duconseil · 3 shared papers, 2017–2021 · strength 0.21
  25. Marine Gilabert · 3 shared papers, 2017–2021 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.